### ADAM12 — A Disintegrin And Metalloprotease

- is highly expressed in e.g. human breast carcinoma cells and correlates with disease stage
- promotes tumor progression in mouse models of cancer
- enhance tumor growth independent of its own proteolytic activity
- regulates MT1-MMP (MMP14) cell surface levels and activity

### Monoclonal antibodies against ADAM12 block MT1-MMP-mediated extracellular matrix (ECM) degradation and cancer cell invasion in vitro

![Image of ECM degradation and cancer cell invasion](image)

#### Value proposition/USP
By using monoclonal antibodies targeting ADAM12 it is possible to prevent metalloprotease MT1-MMP (MMP14)-mediated degradation of the cellular matrix (ECM). Thus, ADAM12 represents a target for anti-invasive and anti-metastatic treatment, which remains an underexplored field in cancer treatment. ADAM12 is expected to be a good cancer drug target because it is expressed at very low levels in normal adult tissues. Yet, it is upregulated upon tissue injury or excessive growth as seen in cancer or re-generation.

#### Business Opportunity/Objectives
The need for novel anti-cancer treatments remains high and the market opportunities significant. ADAM12 antibodies that can be developed into therapeutic compounds or serve as starting points for antibody drug development are available. An example of an important target indication could be glioblastoma, which is extremely invasive. Even as a second or third line treatment, an effective anti-invasive therapy would be of clinical utility. Another early clinical relevant target indication may be pituitary adenomas.

#### Technology description
Two monoclonal antibodies (78B and 8F8), developed by immunization of ADAM12-knockout mice both inhibit ADAM12-induced MMP14 activation without affecting ADAM12’s own enzymatic activity. Specifically, both antibodies inhibit MMP14-mediated gelatin degradation and in vitro invasion of human breast carcinoma cells.

#### Development phase
Novo Seed has supported a pre-seed project. While the two antibodies inhibiting the ADAM12-MMP14 cooperation do not affect tumor cell proliferation in vitro or xenograft growth in vivo, they both have a very strong inhibitory effect on in vitro cancer cell invasion through matrigel (Boyden chamber assay). An effect that is similar to the effect of siRNA-mediated knockdown of MMP14. This is shown in the figure above. These findings are well in line with previous reported observations that both mAbs block the ADAM12-induced MMP14 activation and subsequent enhanced ECM degradation. One of the next steps will be to test the efficacy of the 78B and 8F8 mAbs in experimental metastasis models in mice.

#### The inventors
- Ulla Wever (KU)
- Reidar Albrechtsen (KU)

#### Scientific lead
Marie Kveiborg (KU)

#### Intellectual property rights: PCT application: WO 2015028027

![Image of potential applications](image)